Brazilian National Sanitary Surveillance Agency (ANVISA) Certifies NextBreath, LLC as a Center for In Vitro Pharmaceutical Equivalence

Next Breath is now authorized to conduct Pharmaceutical Equivalence studies for Brazil.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
ANVISA’s certification is an important milestone for Next Breath. The ability to support our partners will be greatly enhanced with Next Breath’s direct engagement of ANVISA.

Baltimore, Maryland (PRWEB) March 31, 2014

Next Breath, LLC is pleased to announce that the Brazilian National Sanitary Surveillance Agency (ANVISA) has certified the company as a Center for Pharmaceutical Equivalence (EQFAR). As a result, Next Breath is now authorized to conduct Pharmaceutical Equivalence studies for Brazil. ANVISA performed a week-long comprehensive audit of Next Breath’s quality systems in November 2013.

The audit focused on ensuring that all quality systems, analytical capabilities, regulatory expertise and statistical expertise meet ANVISA’s rigorous standard for becoming an approved Center for Pharmaceutical Equivalence. The successful audit approves Next Breath for performing in vitro pharmaceutical equivalence and submission of Nasal Sprays, Dry Powder Inhalers (DPIs), and Pressurized Metered Dose Inhalers (pMDIs) to the Brazilian authorities.

Only ANVISA certified laboratories are authorized to perform in vitro pharmaceutical equivalence testing for generic applications in the Brazilian market. The Center for Pharmaceutical Equivalence certification makes Next Breath the only laboratory outside Brazil certified to perform in vitro pharmaceutical equivalence testing for use in the Brazilian market.

Julie Suman, R.Ph., Ph.D. President said, “Next Breath has been committed to working with ANVISA and our Brazilian partners for many years. Recognition as an EQFAR laboratory allows us to bring our scientific expertise and know-how to advance generic drug approvals. We are very pleased with this certification.”

Badre Hammond, MBA, Associate Director of Business Development stated, “ANVISA’s certification is an important milestone for Next Breath. The ability to support our partners will be greatly enhanced with Next Breath’s direct engagement of ANVISA.

Next Breath

Next Breath, a member of AptarGroup, is a cGMP specialty Contract Research Organization (CRO) with analytical expertise for pharmaceutical, biotechnology, and consumer health product development focused on pulmonary, nasal, topical and ophthalmic delivery systems. Next Breath provides comprehensive solutions to the development processes from proof of concept to commercialization. Next Breath has led successful submissions for pulmonary and nasal drug products and devices in the US and international markets.

For more information please visit http://www.nextbreath.net or http://www.aptar.com.

Next Breath Contact:

Badre Hammond. Tel.:+(1)352-642-2141 - E-mail : badre.hammond(at)nextbreath(dot)net


Contact